Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Advanced Solid Tumors 2Advanced Cancer 2Small Cell Lung Cancer Limited Stage 1Sarcoma 1Pancreatic Neoplasms 1Osteosarcoma 1Neoplasms 1Cholangiocarcinoma 1Brain Neoplasms 1Advanced Cervical Cancer 1

Interventions

Cyclophosphamide 14Gemcitabine 6Filgrastim 6fludarabine 5Methotrexate 5Leucovorin 5Granulocyte Colony-Stimulating Factor 5Zoledronic Acid 4Temozolomide 4Mesna 4Irinotecan 4Ifosfamide 4Etoposide 4Cisplatin 4Carboplatin 4pembrolizumab 3fludarabine phosphate 3Doxorubicin 3Biopsy 3tanespimycin 2poly ICLC 2pegfilgrastim 2lorukafusp alfa 2liposomal doxorubicin 2dinutuximab 2cabozantinib 2belinostat 2Topotecan 2Thalidomide 2Specimen Handling 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Osteosarcoma × anlotinib × Clear all
NCT06699576 2024-11-21

ARTEMIS-103: Phase 1b Study of HS-20093 Combinations in Patients with Bone and Soft Tissue Sarcoma.

Hansoh BioMedical R&D Company

Phase 1 Not yet recruiting
448 enrolled
Sarcoma

Sarcoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡